You are now viewing 11 - 20 of 170 results
January 6, 2011 | Human Capital Blog Post
To casual observers, two facts about the U.S. pharmaceutical industry seem to be at odds. On one hand, the industry as a whole is very profitable: It had a 2008 profit margin of 19 percent, and it is regularly at or near the top of Fortune 500 ranki ...
November 1, 2010 | Journal Article
A large value-based insurance design program offered by Blue Cross Blue Shield of North Carolina eliminated generic medication copayments and reduced copayments for brand-name medications.
October 1, 2010 | Journal Article
As comparative effectiveness research becomes a more prominent feature of clinical medicine, investigators and policy-makers would do well to seek lessons from prior examples of this type of research.
June 28, 2011 | Human Capital Blog Post
To examine the extent of medical students’ relationships with industry – as well as the impact of these interactions – my colleagues, Kirsten Austad and Jerry Avorn, M.D., and I conducted a systematic review of the literature, examining all publishe ...
January 1, 2009 | Issue Brief
More children and working-age Americans are going without prescription drugs because of cost concerns, according to a new national study by the Center for Studying Health System Change (HSC).
November 12, 2009 | Journal Article
Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the FDA in 1997. This study reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA.
May 1, 2010 | Journal Article
In this study, nurse interventionists identified and documented medication discrepancies from two Inland Northwest hospitals. The researchers identified more system-level discrepancies than patient-level ones.
October 21, 2009 | Journal Article
This commentary calls for prescription medication labels to more accurately reflect FDA review documents. The FDA is considering adopting "Prescription Drug Facts Boxes" to supply crucial information now absent from many drug labels.
January 5, 2011 | Story
Aaron Kesselheim's New England Journal of Medicine article explores 'myths' about effectiveness of policies aimed at incentivizing development of new drugs.
May 1, 2009 | Journal Article
In this paper, the authors assess how dual eligibles with mental disorders are faring under Medicare Part D.